PIV | Search

Trials

100 participants · First posted Aug 28, 2023

Completed

NCT02239614

TDENV PIV and LAV Dengue Prime-boost Strategy

80 participants · First posted Sep 15, 2014

Withdrawn

NCT03110952

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

First posted Apr 12, 2017

Drugs

View all 488 →

EC-PIV

PIV-3 vaccine

Small Molecule

Approved

Pivampicillin

Conditions: Susceptible Bacterial Infections

C₂₂H₂₉N₃O₆S

Organizations

View all 25 →

Pivot Health Technologies INc.

United States

PMV Pharmaceuticals

United States

CARGO Therapeutics

United States

News

View all 5605 →

last year

Novel Pan-Immune-Inflammation Nomogram Shows Promise in Predicting Epithelial Ovarian Cancer Outcomes

last year

Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants

11 days ago

Trials

Difficult PIV Placement in the Pediatric ED

TDENV PIV and LAV Dengue Prime-boost Strategy

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Drugs

EC-PIV

PIV-3 vaccine

Pivampicillin

Organizations

Pivot Health Technologies INc.

PMV Pharmaceuticals

CARGO Therapeutics

News

Novel Pan-Immune-Inflammation Nomogram Shows Promise in Predicting Epithelial Ovarian Cancer Outcomes

Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants

Clover Reports Positive Phase 2 Data for RSV + hMPV ± PIV3 Combination Vaccines in Older Adults